Insisting on lower prices, federal researchers say, would drive away innovative partners that speed the   process and benefit patients. But with the government doing so much pivotal research, others say that the private sector cannot afford to walk away. " The market is so reliant on the knowledge and   that comes out of the government and academic labs," said Dr. Aaron Kesselheim, director of the Program on Regulation, Therapeutics and Law at Brigham   